

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 9, 2006  
-----

A.P. Pharma, Inc.

-----  
(Exact name of registrant as specified in its charter)

000-16109

-----  
(Commission File Number)

Delaware

94-2875566

-----  
(State or other jurisdiction  
of incorporation)

-----  
(I.R.S. Employer  
Identification No.)

123 Saginaw Drive  
Redwood City, CA 94063

-----  
(Address of principal executive offices, with zip code)

(650) 366-2626

-----  
(Registrant's telephone number, including area code)

N/A

-----  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is  
intended to simultaneously satisfy the filing obligation of the  
registrant under any of the following provisions (see General  
Instruction A.2. below):

- Written communications pursuant to Rule 425 under the  
Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the  
Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b)  
under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c)  
under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election  
of Directors; Appointment of Principal Officer

On October 9, 2006, Michael O'Connell, President and Chief  
Executive Officer of A.P. Pharma, Inc. (the "Company") began a  
temporary leave of absence for medical reasons.

Effective that same date, the Company's Board of Directors  
appointed Gregory Turnbull, formerly an independent director of  
the Company, to serve as President and Chief Executive Officer  
until Mr. O'Connell's return. Paul Goddard, Chairman of the  
Company's Board of Directors, will work closely with Mr.  
Turnbull in oversight of the Company's affairs. Concurrently,  
Mr. Turnbull resigned from the Board's audit, compensation and  
nominating committees.

Mr. Turnbull has been a director of the Company since  
February 1986 and will continue to act as a director. Mr.  
Turnbull is currently a business consultant and has considerable  
experience working with development-stage companies.  
Previously, he was a general partner of Cable & Howse Ventures,  
a venture capital firm, and also served as an investment banker

with Morgan Stanley & Co. and White, Weld & Co. Mr. Turnbull also serves as Chairman of the Board for Planar Systems, Inc. and as a director of certain privately-held companies.

In connection with his part-time service as President and Chief Executive Officer, Mr. Turnbull will receive compensation of \$15,000 per month, payable in accordance with the Company's customary payroll practices. Additionally, on October 9, 2006, Mr. Turnbull was granted an option to purchase 65,000 shares of the Company's common stock at its closing price on that date. The option will vest and become exercisable on the earlier of April 9, 2007, or the last day of Mr. Turnbull's service as President and Chief Executive Officer. Mr. Turnbull will also continue to receive the customary compensation paid by the Company to its outside directors.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

A.P. PHARMA, INC.

Date: October 9, 2006  
-----

By: /s/ Stephen C. Whiteford  
-----

Stephen C. Whiteford  
Vice President, Finance and  
Chief Financial Officer